Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.4961
+0.0369 (8.04%)
Jul 28, 2026, 2:44 PM EDT - Market open
Heron Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 26.12 | 28.65 | 25.8 | 28.68 | 15.36 | 90.54 |
Short-Term Investments | 18.67 | 17.98 | 33.48 | 51.73 | 69.49 | 67.04 |
Cash & Short-Term Investments | 44.78 | 46.63 | 59.28 | 80.41 | 84.85 | 157.58 |
Cash Growth | -11.63% | -21.34% | -26.27% | -5.24% | -46.15% | -24.42% |
Accounts Receivable | 83.69 | 89.59 | 78.88 | 60.14 | 52.05 | 35.5 |
Inventory | 92.54 | 92.75 | 53.16 | 42.11 | 54.57 | 48.38 |
Other Current Assets | 7.97 | 9.1 | 17.69 | 6.12 | 13.96 | 12.96 |
Total Current Assets | 228.98 | 238.07 | 209.01 | 188.77 | 205.44 | 254.42 |
Net Property, Plant & Equipment | 12.03 | 12.4 | 17.65 | 25.6 | 29.81 | 33.56 |
Other Long-Term Assets | 5.21 | 5.41 | 6.48 | 8.13 | 15.71 | 17.72 |
Total Assets | 246.22 | 255.88 | 233.15 | 222.51 | 250.95 | 305.71 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 8.97 | 8.99 | 11.71 | 3.24 | 3.23 | 3.8 |
Accrued Expenses | 81.55 | 87.1 | 76.71 | 73.37 | 76.44 | 64.84 |
Current Portion of Leases | - | - | 3.04 | 3.08 | 2.69 | 2.42 |
Total Current Liabilities | 90.52 | 96.1 | 91.46 | 79.69 | 82.36 | 71.06 |
Long-Term Debt | 141.63 | 140.64 | 174.73 | 173.75 | 149.28 | 149.08 |
Long-Term Leases | - | - | - | 2.8 | 5.5 | 8 |
Other Long-Term Liabilities | 4.93 | 4.81 | 0.62 | 0.24 | 0.24 | - |
Total Long-Term Liabilities | 146.56 | 145.45 | 175.34 | 176.79 | 155.02 | 157.08 |
Total Liabilities | 237.08 | 241.54 | 266.8 | 256.48 | 237.38 | 228.14 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | 1.05 | 1.05 | - | - | - | - |
Common Stock | 1.89 | 1.88 | 1.52 | 1.5 | 1.19 | 1.02 |
Additional Paid-in Capital | 1,954 | 1,951 | 1,884 | 1,871 | 1,808 | 1,690 |
Accumulated Other Comprehensive Income | -0.01 | 0 | 0.01 | 0.01 | -0.02 | -0.01 |
Retained Earnings | -1,948 | -1,940 | -1,920 | -1,906 | -1,795 | -1,613 |
Shareholders' Equity | 9.14 | 14.33 | -33.65 | -33.97 | 13.57 | 77.57 |
Total Liabilities & Equity | 246.22 | 255.88 | 233.15 | 222.51 | 250.95 | 305.71 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 141.63 | 140.64 | 177.76 | 179.63 | 157.48 | 159.5 |
Net Cash (Debt) | -96.85 | -94.01 | -118.48 | -99.22 | -72.63 | -1.92 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.55 | -0.56 | -0.78 | -0.72 | -0.67 | -0.02 |
Book Value | 9.14 | 14.33 | -33.65 | -33.97 | 13.57 | 77.57 |
Book Value Per Share | 0.05 | 0.09 | -0.22 | -0.25 | 0.12 | 0.79 |
Tangible Book Value | 9.14 | 14.33 | -33.65 | -33.97 | 13.57 | 77.57 |
Tangible Book Value Per Share | 0.05 | 0.09 | -0.22 | -0.25 | 0.12 | 0.79 |